NZ537821A

NZ537821A - Anti-viral compositions useful for treating one or more adverse effects of viral infections

Info

Publication number: NZ537821A
Application number: NZ537821A
Authority: NZ
Inventors: Richard A Rosenbloom
Original assignee: The Quigley Corp
Priority date: 2002-08-06
Filing date: 2003-07-24
Publication date: 2007-05-31
Also published as: CA2495447A1; WO2004012655A3; WO2004012655A2; AU2003256736B2; EP1545470A2; JP2005534699A; CN1674875A; IL166608A0; MXPA05001051A; EP1545470A4; HK1082660A1; AU2003256736A1

Abstract

Disclosed is an anti-viral composition which includes a first ingredient obtained from ginger, a second ingredient obtained from green tea, a third ingredient available from turmeric, and an acceptable carrier. The first and second ingredients are present in an amount which when combined is effective to reduce, treat or prevent an adverse effect of a viral infection when administered to a patient prior to expected exposure to a virus, concurrently with exposure to a virus or after exposure to a virus.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 537821 617S*I 1 ANTI-VIRAL COMPOSITIONS AND METHODS OF USING SAME BACKGROUND OF THE INVENTION A. Field of the Invention The present invention relates to anti-viral compositions and methods of using them. More particularly, the present invention relates to anti-viral compositions useful for treating one or more adverse effects of iviral infections, and to methods for administering the anti-viral compositions. B. Description of the Prior Art Treatment of Microbial Infections The medical literature regarding anti-microbial agents is vast and describes a number of anti-microbials including naturally occurring compounds as well as synthetic or semi-synthetic compounds produced in the laboratory. Consumers today often prefer to use naturally occurring compounds when these are available. Due to concern over side effects, which may be well documented side effects that occur in conjunction with a treatment, or possibly unknown side effects that may result from long-term use of a treatment, many consumers especially prefer anti-microbial treatments that are prepared from natural materials, such as herbs, with a minimal amount of chemical processing. Treatment of Inflammation Inflammation can result from microbial infections. In modem non-herbal medicine, there are two. major categories of anti-inflammatory medicines: steroidal and non-steroidal. Steroidal anti-inflammatory medicines are powerful medications, which are based on hormonal substances, such as cortisone. Steroidal medications have a stronger anti-inflammatory response than non-steroidal medicines. Steroidal medications can be taken as pills, injected into the bloodstream, or injected directly into a joint space. There are many non-steroidal anti-inflammatory medications. Acetaminophen, aspirin, ibuprofen, and naproxen are the most commonly used nonsteroidal anti-inflammatory medications. intellectual property office of n.z. 19 SEP 2006 R E C FI \/ P n 2 (followed by page 2a) Non-steroidal anti-inflammatory drugs have three major actions, all of which are related to inhibition of cyclo-oxygenase resulting in decreased formation of prostanoids. Firstly, an anti-inflammatory action can be achieved by reducing production of vasodilator prostaglandins (PGE2, PGI2), which means less vasodilation and, indirectly less oedema. Secondly, an analgesic effect can be achieved by reduced prostaglandin production (less sensitization of nociceptic nerve endings to the inflammatory mediators bradykinin and 5-hydroxytryptamine). Thirdly, an antipyretic Effect can produce an anti-inflammatory action, probably due to a decrease in the mediator PGE2 generated in response to inflammatory pyrogens, much as interleukin-1. There are side effects to both of these groups of medicines. They may include, among other things, stomach upset, stomach bleeding, or ulcers, kidney problems, hearing problems and ankle swelling. Additionally, the steroidal anti-inflammatory medications can have more serious side effects including: loss of bone mass, cataracts, reduced ability to fight infection, swelling and weight gain, mood changes, high blood pressure, and problems with the bone marrow where blood cells are produced. It is therefore an object of certain embodiments of the present invention to provide an anti-viral composition or to provide an anti-viral composition made from natural products or to provide a method for treating viral infections by administering an anti-viral compositioh or to provide a method to treat microbial infections by administering a composition made from natural products or to at least provide the public with a useful choice. These and other objects of the present invention will be apparent from the summary and detailed description of the invention, which follow. SUMMARY OF THE INVENTION In one aspect the present invention provides an anti-viral composition comprising: intellectual property office of n.z. 19 SEP 2006 RECEiVFn 2a (followed by page 3) a first ingredient selected from ginger extract, ginger powder, at least a part of a whole plant of ginger, ginger tincture, and mixtures thereof; a second ingredient selected from green tea powder, green tea extract, at least a part of a whole plant of green tea, tinctures of green tea and mixtures thereof; a third ingredient selected from turmeric extract, turmeric powder, one or more curcuminoid compounds, at least a part of a whole plant of turmeric, turmeric tincture and mixtures thereof; and an acceptable carrier; wherein the first ingredient and second ingredients are present in the anti-viral composition in an amount which, when combined, is effective to reduce, treat or prevent an adverse effect of a viral infection when administered to a patient prior to expected exposure to a virus, concurrently with exposure to a virus, or after exposure to a virus. In another aspect the present invention provides an anti-viral composition comprising: turmeric extract; ginger root powder; a green tea extract; and an acceptable carrier; wherein the ginger root powder, green tea extract and turmeric extract are present in the anti-viral composition in an amount which, when combined, is effective to reduce, treat or prevent an adverse effect of viral infection when administered to a patient prior to expected exposure to a virus concurrently with exposure to a microbe, or after exposure to a' virus. In another aspect the present invention provides use of < a composition comprising: a first ingredient obtained from ginger; a second ingredient obtained from green tea; and an acceptable carrier; for the manufacture of a medicament.for the reduction, treatment or prevention of at least one adverse effect of a viral infection. Described is an anti-microbial composition comprising a first ingredient obtainable from ginger, a second ingredient obtainable from green tea, and, optionally, an acceptable carrier, wherein the first ingredient is 1 ,l)"< intellectual propert* OFFICE OF N.z. 2 2 MAR 2007 (followed by page 3 a) present in the anti-microbial composition in an amount effective to reduce, treat or prevent an adverse effect of microbial infection when administered to a patient prior to expected exposure to a microbe, concurrently with exposure to a microbe, or after exposure to a microbe. Also described is a method for the reduction, treatment or prevention of at least one adverse effect of microbial infection in a patient, comprising the step of administering to the patient prior to expected exposure to a microbe, concurrently with exposure to a microbe, or after exposure to a microbe, an amount of a composition comprising a first ingredient obtainable from ginger, a second ingredient obtainable from green tea, and, optionally, an acceptable carrier. The composition is effective, when administered, to reduce, treat or prevent an adverse effect of microbial infection in the patient. The term "comprising" as used in this specification and claims means "consisting at least in part of'; that is to say when interpreting statements in this specification and claims which include "comprising", the features prefaced by this term in each statement all need to be present but other features can also be present. Related terms such as "comprise" and "comprised" are to be interpreted in similar manner. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Described is an anti-microbial composition. The anti-microbial composition described herein includes ingredients that can be obtained from ginger arid green tea. As used herein the term "flavors" includes both fruit and botanical flavors. As used herein the term "sweeteners" includes sugars, for example, glucose, sucrose and fructose. Sugars also include high fructose corn syrup solids, invert sugar, sugar alcohols including sorbitol, and mixtures thereof. Artificial sweeteners are also included within the scope of the term, "sweetener." As used herein, the term "acceptable" means a component that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic responses), commensurate with a reasonable risk/benefit ratio. intellectual property office of n.z. 19 SEP 2006 755629_1.DOC 3a (followed by page 4) Farther, as used herein, the term "safe and effective amount" refers to the quantity of a component, which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic responses), commensurate with a reasonable risk/benefit ratio when used in the manner described herein. The term "inhibiting" a microbe, as used herein, is meant reducing or preventing further growth of the microbe, and/or the elimination of some or all of the 755629_1.DOC INTELLECTUAL PRUrtn. OF N.Z. 1 9 SEP 2006 4 microbe from the human or animal being treated. Suitable methods for determining microbe inhibition are discussed in the examples. All active compounds used in the present invention may be obtained from other sources, if available. Thus, the phrase "which can be obtained from" or the 5 phrase "which may be obtained from" is meant to encompass compounds or compositions that are obtainable from turmeric, ginger, or green tea, and therefore encompasses synthetic forms of the same compounds and/or compositions as well as the same compounds and/or compositions obtained from other sources. Most preferably, the anti-microbial composition described herein 10 includes a first ingredient obtainable from ginger and a second ingredient obtainable from green tea, in a safe and effective amount to provide one or more of the beneficial effects described herein. The first ingredient of the anti-microbial composition described herein may be obtained from ginger (Zingiber officinale, also commonly called ginger root). 15 Native to southern Asia, ginger is a 2- to 4-foot perennial that produces grass-like leaves up to a foot long and almost an inch wide. Ginger root, as it is called in the grocery store, actually consists of the underground stem of the plant, with its bark-like outer covering scraped off. Chinese medical texts from the fourth century B.C.E. suggest that ginger is 20 effective in treating nausea, diarrhea, stomachaches, cholera, toothaches, bleeding, and rheumatism. Ginger was later used by Chinese herbalists to treat a variety of respiratory conditions, including coughs and the early stages of colds. Ginger's modern use dates back to the early 1880s, when a scientist named D. Mowrey noticed that ginger-filled capsules reduced his nausea during an episode of 25 flu. Inspired by this, he performed the first double-blind study of ginger. Germany's Commission E subsequently approved ginger as a treatment for indigestion and motion sickness. Ginger has become widely accepted as a.treatment for nausea. Even some conventional medical texts suggest ginger for the treatment of the nausea and vomiting of pregnancy, although others are more cautious. 30 Ginger gives relief from muscular discomfort and pain. It inhibits prostaglandin and leukotriene biosynthesis and histamine release. Thus it acts as an anti-inflammatory as well as an antacid agent. It is a dual inhibitor of the lipoxigenase and cycloxigenase system. Ginger contains about 1 omcE OF N.Z. 1 9 SEP 2006 REC Fi\/rn 6 y-terpinene, geranial, geraniol, geranyl-acetate, gingerenone, glutamic acid, glycine, hexahydrocurcumin, histidine, isogingerenone-B, isoleucine, kaempferol, lecithin, limonene, linoleic acid, magnesium, manganese, methionine, mufa, myrecene, myricetin, myristic acid, neral, nerol, nerolidol, niacin, nickel, oleic acid, oxalic acid, 5 p-coumaric acid, p-cymene, p-hydroxy-benzoic acid, palmitic acid, pantothenic acid, paradol, patchoulic alcohol, phenylalanine, quercetin, riboflavin, selenium, shikimic-acid, terpinen-4-ol, thiamin, tryptophan, vanillic acid, vanillin, zinc, and zingerone. Also, mixtures of two or more of these active compounds may be employed. The first ingredient of the composition of the present invention, which may be 10 obtained from ginger, can be incorporated in the anti-microbial composition described herein in many different forms including extracts such as ginger powder extracts, ginger fluid extracts, ginger powder including ginger root powder, and one or more active compounds of ginger, parts of, or whole ginger plants, tinctures thereof, and mixtures thereof. Preferably, the first ingredient of the anti-microbial 15 composition of the present invention is selected from ginger extract, and ginger root powder. Each gram of the anti-microbial composition 'described herein preferably contains about 30 mg to about 150 mg of ginger root powder. Most preferably, each gram of the anti-microbial composition contains about 50 mg to 20 about 110 mg of ginger root powder. These ranges use, as a baseline, the use of Ginger Root Powder, ex. Stryka Botanies in the ingested formulation and Ginger Extract K (Aquaresin Ginger), ex. Kalsec, Inc. of Kalamazoo, Michigan in the spray formulation. The amounts of various ingredients are given herein in terms of one form of 25 the ingredient, i.e. ginger root powder. If that ingredient is present in another form, then the amount to be employed is that amount which will provide the same amount of the one or more active compounds as the amount of that ingredient given herein. For example, if a tincture of ginger is employed, the amount of the tincture employed will be the amount that pro vides the same amounts of one or more active compounds 30 as would be provided by the amounts of ginger root powder specified above. This applies to all ingredients for which the amounts are given herein for one particular form of that ingredient. intellectual property office of n.z. 19 SEP 2006 RCrcitffr* I The second ingredient of the anti-microbial composition of the present invention may be obtained from green tea. The second ingredient obtained from green tea may have an antioxidant effect. Green tea is the dried leaves and leaf buds of the shrub Camellia sinensis. It is mainly produced in China and Japan. Dried tea leaves are composed mainly of phytochemicals known as polyphenols (about 36%), principally flavonols (including catechins), flavonoids, and flavondiols. The leaves also contain plant alkaloids (about 4%), including caffeine, theobromine and theophylline. Much of the research on green tea has been focused on its potential to prevent cancer. Research suggests that the polyphenols in green tea are responsible for a chemopreventive effect (E. Kaegi, Canadian Medical Association Journal. 1998, 158: 1033-35). The pharmacological activities of green tea are mainly due to its active compounds. The active compounds of green tea useful in the present invention include, but are not limited to, flavonols, catechins, flavonoids, flavondiols, plant alkaloids, caffeine, theobromine, theophylline, phenolic acids, proteins, carbohydrates, and minerals. The second ingredient which may be obtained from green tea, can be included in the anti-microbial composition in the form of green tea powder, green tea extracts such as green tea powder extracts, green tea fluid extracts, and one or more active compounds of green tea, part of, or whole green tea plants, green tea leaves, tinctures thereof, or mixtures thereof. Preferably, the second ingredient of the anti-microbial composition described herein is selected from green tea leaves, green tea powder and green tea extract. More preferably, the second ingredient of the antimicrobial composition of the present invention is green tea extract. Each gram of the anti-microbial cbmposition described herein j l preferably contains about 5 mg to about 20 mg of green tea extract. Most preferably, each gram of the anti-microbial composition contains about 7 mg to about 15 mg of green tea extract. These ranges use, as a baseline, the use of Green Tea, ex. Stryker Botanies in the ingested formulation and Green Tea Extract, ex. Phytoway, Inc., ChanSha, P.R. China, in the spray formulation. Also preferably, the anti-microbial composition described herein includes, as an optional ingredient, one or more ingredients obtainable from turmeric, intellectual property office of n.z. 1 9 SEP 2006 D C r r i \ # r r\ I The yellow pigment of the rhizome of turmeric is composed of three compounds known as curcuminoids. The three curcuminoids are curcumin (diferuloylmethane), desmethoxycurcumin (hydroxycinnamoyl feruloylmethane), and bis-desmethoxycurcumin (dihydroxydicinnamoyl methane) (see Drug Analysis by 5 Chromatography and Microscopy, p. 169, Ann Arbor Science Inc., 1973). The essential oils of turmeric (curcuma longa) are primarily composed of the following compounds: d-camphor (about 1%), cyclo-isoprenemyrcene (about 85%), and p-tolylmethylcarbinol (about 5%), (see E. Gunther. The Essential Oil, pp. 123-4, Van Nostrand Co., 1955). 10 The optional ingredient of the composition of the present invention, obtained from turmeric, preferably includes curcuminoids, such as curcumin (diferuloylmethane), desmethoxycurcumin (hydroxycinnamoyl feruloylmethane), and bis-desmethoxycurcumin (dihydroxydicinnamoyl methane), and mixtures of two or more of these curcuminoids. 15 Methods for isolating curcuminoids from turmeric are known (see Janaki and Bose, An Improved Method for the Isolation of Curcumin From Turmeric, j. Indian Chem. Soc. 44:985 (1967)). Alternatively, curcuminoids for use in the present invention can be prepared by synthetic methods. The optional ingredient, which can be obtained from of turmeric, can be 20 incorporated into the composition of the present invention in a variety of different forms. Those different forms preferably include extracts of turmeric such as turmeric powder extracts, turmeric fluid extracts, one or more the curcuminoid compounds, and turmeric powder, parts of, or whole plants of turmeric, tinctures thereof, and mixtures thereof. More preferably > the optional ingredient obtainable from turmeric is a 25 turmeric extract. When the optional ingredient obtainable from turmeric is used, each gram of the anti-microbial composition described herein preferably contains about 5 mg to about 20 mg of turmeric powder extract. Most preferably, each gram of the anti-microbial compositions contains about 7 mg to about 15 mg of turmeric powder 30 extract. These ranges are based on the use of Turmeric Extract 95%, ex. Pharmline, Inc. in the ingested formulation and Turmeric Root Extract (Oleoresin Turmeric), ex. Kalsec, Inc., Kalamazoo, Michigan, in the spray formulation. intellectual property office OF N.Z. 19 SEP 2006 10 The ingredients of the anti-viral composition of the present invention, which may be obtained from ginger and green tea, and, optionally, turmeric, may be used in the forms of turmeric powder, ginger powder and green tea powder, each of which may be ground from the rhizome of turmeric, ginger root and green tea leaves, respectively. For a particular active compound of ginger, green tea or turmeric, for which a synthetic route is known, the active compound may be synthesized. The plant extracts, if desired, may be prepared as described below. Alternatively, turmeric powder, ginger powder, green tea powder and/or one or more of the active compounds contained therein may be purchased from commercial sources such as the Delavau Co. of Philadelphia, PA. The plant extracts, e.g., turmeric extract, ginger extract and green tea extract, that may be used in the compositions of the invention, may be produced using common extraction procedures. Alternatively, the extracts may be purchased from commercial sources such as the Delavau Co. of Philadelphia, PA. One suitable extraction procedure comprises, generally, the steps of: 1) cleaning the plant from which the pharmacologically or biologically active plant extract is to be obtained to remove any foreign matter thereon; 2) particulating the plant to obtain a particulate mass having particle size ranging from 0.001 to about 10 mm3; and 3) subjecting the particulate mass to at least one polar and at least one non-polar solvent to obtain separate fractions of plant extract soluble in the respective solvents, and mixing the fractions so obtained to obtain the beneficiated plant extract in accordance with this invention. For instance, in the case of turmeric, the process comprises the steps of: 1) cleaning the roots of turmeric to remove any foreign matter thereon; 2) particulating the roots to obtain a particulate mass having particle size ranging from 0.001 to about 10 mm3; 3) subjecting the particulate mass to distillation to obtain a volatile fraction, if any, from the particulate mass; 4) cooking the distilled particulate mass in a polar solvent, such as water to solubulize material in the distillation-treated particulate mass to obtain first solution and a first residue; 5) filtering the first solution from the first residue; 18 SEP 2008 n r— —* - 11 6) evaporating the filtrate obtained from the first solution to remove the solvent and obtain a solute designated as fraction A obtained from the particulate mass; 7) subjecting the first residue to treatment with a second polar solvent such as 75% to 95% ethanol for twelve to thirty-six hours to obtain a second solution and a second residue; 8) filtering the second solution from the second residue to obtain a second filtrate; 9) evaporating the second filtrate to remove its solvent and obtain a solute designated as fraction B obtained from the particulate mass; 10) subjecting the second residue to less polar or non-polar solvents, such as petroleum ether, for twelve to thirty-six hours to obtain a third solution and a third residue, and filtering the third solution from the third residue to obtain a third filtrate; 11) evaporating the third filtrate to remove its solvent and obtain a solute designated as fraction C obtained from the particulate mass; and 12) homogeneously mixing the volatile fraction, with fractions A, B and C from the particulate mass to obtain a beneficiated plant extract. The process is suitable for the preparation of pharmacologically or biologically active plant extracts in a convenient, administrable dosage form from any of the plants mentioned above. Solvents useful for extracting turmeric include water, ethanol, propanol, paraffin, hexane, petroleum ether, toluene, acetone, methyl ethyl ketone, and other common organic solvents. Water, ethanol and petroleum ether are the preferred solvents for extracting turmeric. Solvents useful for extracting ginger include water, ethanol, propanol, paraffin, petroleum ether, hexane, toluene, acetone, methyl ethyl ketone, and other common organic solvents. Ethanol, water and acetone are the preferred solvents for extracting ginger. The anti-microbial composition described herein may be used to treat microbial infection, since the composition has significant anti-microbial properties as demonstrated by the examples of this application. The anti-microbial composition may also be used as a therapeutic composition to treat one or more symptoms of a microbial infection, including sore intellectual property office of n.z. 19 SEP 2006 12 throat, congestion, laryngitis, mucositis, and/or mucous membrane inflammation by administration to a patient suffering from one or more of these symptoms or ailments. ' / Viruses that may be inhibited by the antimicrobial/composition includes, among other viruses, rhinoviruses, respiratory syncytial virus 5 (RSV), Herpes viruses, influenza viruses, HIV-viruses and the West Nile virus. In a preferred embodiment, the viruses that may be inhibited by the antimicrobial composition include at least Kumari rhinovirus 16, Herpes I Virus (HSV-1), Influenza A/Moscow/10/99, and B/Guangdong/120/00. The anti-microbial composition of the present invention may also be used to 10 treat bacterial infections, such as streptococcal infections, and fungal infections, for example by yeasts such as Candida. Preferably, the anti-microbial composition may be formulated in any acceptable dosage form including, but not limited to, capsules, tablets, lozenges, troches, hard candies, powders, sprays, gels, elixirs, syrups, and 15 suspensions or solutions. The anti-microbial composition may also be administered in the form of a nutritional supplement, in which case the composition of the invention may be the nutritional supplement or may form a part of a nutritional supplement containing additional ingredients. The anti-microbial composition may also be 20 formulated with an acceptable carrier. The acceptable carrier may include, but is not limited to: (a) carbohydrates including sweeteners, more preferably, fructose, sucrose, sugar, dextrose, starch, lactose, maltose, maltodextrins, corn syrup solids, honey solids, commercial tablet nutritional supplements including Emdex™, Mor-Rex™, Royal-T™, Di-Pac™, Sugar-Tab™, Sweet-Rex™, and New-Tab™; (b) sugar 25 alcohols including mannitol, sorbitol and xylitol; and (c) various relatively insoluble excipients including dicalcium phosphate, calcium sulfate, calcium carbonate, microcrystalline cellulose and other tableting ingredients. Lozenges, tablets, and troches in this invention may differ in shape, size and manufacturing technique. In the case of tablets, for oral use, the acceptable carrier 30 may further include lactose and corn starch. Lubricating agents may also be added to the tablets, including, for example, magnesium stearate, sodium lauryl sulfate and talc. Tablets may also contain excipients such as sodium citrate, calcium carbonate and calcium phosphate. Disintegrants such as starch, alginic "ilirflt?", j iniellectlwl property office of N.z. 1 9 SEP 2006 3 C ^ r i i . — I 13 may also be employed. Tablets may also include binding agents such as polyvinylpyrrolidone, gelatin, PEG-8000 and gum acacia. In the case of lozenges for oral use, the common acceptable carrier may further include a binder such as PEG-8000. Preferably lozenges weigh about 0.1 to about 15 grams to provide a suitable dissolution rate when taken orally. More preferably, lozenges weigh about 1 to about 6 grams. To make compressible lozenges, the active ingredients are added to PEG-8000 processed fructose; or the active ingredients of the anti-microbial composition are added to crystalline fructose and commercially available, sweet, direct compression products such as Mendell's Sugartab™, Sweetrex™, or Emdex™. Sweeteners such as saccharin may be added, if desired, flavors as desired, glidants, such as silica gel, as needed, and lubricants, such as magnesium stearate, as needed. The mixture should be kept dry and tableted soon after mixing. The ingredients are mixed and directly compressed into lozenges using conventional pharmaceutical mixing and tableting equipment. The compressive force is preferably sufficient to produce maximum hardness throughout the lozenges, to preserve a suitable dissolution rate, and to maximize the efficacy of the lozenges. Dissolution of the lozenges, when taken orally, should occur over a sustained period of time, that being about 5 to 60 minutes, and preferably about 20 to 30 minutes. The anti-microbial composition is preferably stored in an airtight container and in a cool dark place. Tablets and troches can be manufactured using procedures similar to that described above with minor changes in the optional ingredients. Such changes are within the skill of the ordinary skilled artisan. Alternatively, the anti-microbial composition may be formulated in liquid form, such as syrups, mouthwashes or sprays, with a solvent or dispersant such as water, or other liquids and optionally in a pharmaceutical^ acceptable carrier, for repeated delivery of the anti-microbial composition to oral and oropharyngeal mucous membranes over a sustained period of time. Preferably, the treatment time is about 5 to 60 minutes, and more preferably about 20 to 30 minutes, so as to permit a prolonged contact of the anti-microbial composition with mouth and throat tissues. Alternatively, such formulations can be in a concentrated form suitable for dilution with water or other materials prior to use. intellectual property office OF N.Z. 19 SEP 2006 14 The anti-microbial composition may also be formulated in chewable forms, such as soft candy, gum drops, liquid filled candies, and chewing gum bases, or in the form of dental products, such as toothpastes and mouthwashes. In use, the chewable composition is preferably retained in the mouth o ver a sustained period of time of 5 preferably about 5 to 60 minutes, and more preferably about 20 to 30 minutes. Dental products may be used in the ordinary manner of using such products. The anti-microbial composition may be formulated in capsule form, with or without diluents. For capsules, useful diluents include lactose and dried corn starch., When suspensions are employed, emulsifying and/or suspending agents 10 may be employed in the suspensions. In addition, solid compositions including one or more of the ingredients of the lozenges described above may be employed in soft and hard gelatin capsules. The anti-microbial composition may also be formulated into a nasal aerosol or inhalant composition. Such a composition may be 15 prepared using well-known techniques. For these types of formulations, suitable carriers may include the following ingredients: saline with one.or more preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or conventional solubilizing or dispersion agents. Other materials, which may optionally be included in the anti-microbial 20 composition, include resveratrol (trihydroxystilbene), inositol, other B-complex vitamins, and additional anti-inflammatories. Also, ingredients such as sweeteners, flavorants, coloring agents, dyes, preservatives, emulsifying agents, suspending agents, melting agents, excipients, demulcents and solvents or diluents such as water, ethanol, propylene glycol, glycerin and various combinations thereof, 25 may be included in the anti-microbial composition. The optional sweeteners which may be used in the anti-microbial composition of the present invention include, but are not limited to, saccharin, aspartame, cyclamates, acesulfame K, neohesperidin dihydrochalcone, other super sweeteners, and mixtures thereof, which may be added to the carrier in amounts sufficiently low 30 so as not to chemically interact with the main ingredients of the anti-microbial composition. The optional flavorants which may be used in the anti-microbial composition include, but are not limited to, peppermint, peppermint- intellectual property OFFICE of n.z. 19 SEP 2006 15 menthol, eucalyptol, wintergreen, licorice, clove, cinnamon, spearmint, cherry, lemon, orange, lime, menthol and various combinations thereof. Preferably, the main ingredients described above/that may be derived from ginger and green tea, make up from about 0.5 to about 90% by weight of the total 5 composition. More preferably, the main ingredients will make up about 10 to about 70% by weight of the total composition. Most preferably, the main ingredients make up about 20 to about 40% by weight of the total composition. The non-carrier ingredients of the anti-microbial composition, including the ingredients obtainable from turmeric, ginger, and green tea as discussed above, can be 10 increased or decreased proportionally in the anti-microbial composition ■ depending on the amount of carrier used in the anti-microbial composition, without substantially affecting the effectiveness of the anti-microbial composition for its intended use. Described is a method of reducing, 15 treating or preventing of at least one symptom or adverse effect of microbial infection by administering, to a patient infected with a microbe, an anti-microbial composition of the present invention, including ingredients that can be obtained from ginger and green tea. In the method, the patient may be a human, an in vitro cell, or an animal. 20 Preferably, the patient is a mammal; more preferably, a human. In the method, the virus that may be inhibited by administration of the anti-microbial composition of the present invention includes, among other viruses, rhinoviruses, respiratory syncytial virus (RSV), Herpes viruses, influenza viruses, HIV-viruses and the West Nile virus. In a preferred embodiment* the viruses that may be inhibited by administration of the 25 anti-microbial composition include at least human rhinovirus 16, Herpes I Virus (HSV-1), Influenza A/Moscow/10/99, and B/Guangdong/120/00. The anti-microbial composition described may also be used to treat bacterial infections, such as streptococcal infections, and fungal infections, for example by yeasts such as Candida. 30 The symptoms, caused by a microbial infection, that may be treated, reduced, or at least partially prevented by this method of the present invention, may include one or more of headache, joint pain, fever, cough, sneezing, muscle ache, running nose, dry mouth, dizziness, and other symptoms related to n^^^Hnfection, property office of n.z. 1 9 SEP 2006 RPOriwirn WO 2004/012655 PCT/US2003/023125 16 The effective amount of the anti-microbial composition will vary depending on such factors as the patient being treated, the particular mode of administration, the activity of the particular active ingredients employed, the age, bodyweight, general health, sex and diet of the patient, time of administration, rate of excretion, the 5 particular combination, of ingredients employed, the total content of the main ingredient of the composition, and the severity of the illness or symptom. It is within the skill of the person of ordinary skill in the art to account for these factors. The anti-microbial composition may be administered about 1 to about 15 times per day, as needed, more preferably, about 2 to about 12 times per day, as needed, or 0 most preferably, about 6 to about 10 times per day, as needed. The anti-microbial composition of the present invention may be administered in any acceptable dosage form including, but not limited to, tablets, capsules, lozenges, troches, hard candies, powders, oral sprays, nasal sprays, gels, elixirs, syrups, chewable compositions, dental products, suspensions, and solutions. 5 Each dosage of the anti-microbial composition contains a safe and effective amount of the anti-microbial composition of the present invention. An effective amount for each therapeutic administration contains a total of about 0.1 gram to about lgram of the ingredients, which may be obtained from ginger and green tea. More preferably, an effective amount of the anti-microbial composition for each therapeutic 0 administration contains a total of about 0.2 gram to about 0.5 gram of the ingredients which may be obtained from ginger and green tea. The amounts of the various ingredients of the composition administered in accordance with the method of the present invention are the same as given above for the composition of the present invention. 5 Preferably, during each oral administration of the anti-microbial composition, the composition is held in the mouth for at least about 5 to about 60 minutes to enable the main ingredients of the anti-microbial composition to contact the mouth tissue or throat before it completely dissolves. More preferably, the anti-microbial composition is held in the mouth for at least about 15 to about 30 minutes. 0 The following preferred ranges define compositions according to the invention that are suited for administration in a spray formulation according to the methods of the invention. Each gram of the antimicrobial composition administered in a spray according WO 2004/012655 PCT/US2003/023125 17 to the methods of the present invention preferably contains about 1 mg to about 10 mg of aquaresin ginger. Most preferably, each gram of the antimicrobial composition contains about 3 mg to about 7 mg of aquaresin ginger. Each gram of the anti-microbial composition administered in a spray 5 according to the methods of the present invention preferably contains about 1 mg to about 20 mg of green tea leaf extract. Most preferably, each gram of the antimicrobial composition contains about 7 mg to about 15 mg of green tea leaf extract. When an optional ingredient from turmeric is used, each gram of the antimicrobial composition administered in a spray according to the methods of the present 0 invention preferably contains about 1 mg to about 12 mg of soluble oleoresin turmeric. Most preferably, each gram of the anti-microbial composition contains about 4 mg to about 9 mg of soluble oleoresin turmeric. As discussed above, the composition of the present invention may be administered in any orally acceptable dosage form including, but not limited to 5 tablets, capsules, lozenges, troches, hard candies, powders, oral sprays, nasal sprays, gels, elixirs, syrups, chewable compositions, dental products, suspensions, and solutions. The invention will be further illustrated by the examples given below which are not to be construed as limiting the invention in any way. The scope of the 0 invention is to be determined by the claims appended hereto. Example 1 - An Anti-microbiai Composition of the Present Invention An anti-microbial composition of the present invention formulated in the form of lozenges was prepared using the procedure described above. The ingredients of the 5 lozenge are listed below: Sugar lg Slippery elm bark 118 mg Turmeric extract (5% curcumin) 18 mg Ginger root 140 mg Horseradish root 70 mg Green tea leaf extract (30% catechin and polyphenols) 14 mg WO 2004/012655 PCT/US2003/023125 18 Example 2 - Treatment of Sore Throat Each of seven patients, suffering from sore throats, ingested one lozenge formulated according to Example 1 every two hours by holding the lozenge in his or her mouth for about 15-30 minutes until the lozenge completely dissolved. No patient 5 took more than 10 lozenges in any given day. The patients that were treated reported complete relief from the symptoms of their sore throats after ingesting from 2 to 20 lozenges. It was also found that each lozenge can provide relief from a sore throat for up to 6 hours. 10 Example 3 - In Vitro Testing of Virucidal Activity of the Anti-microbial Composition The in vitro testing protocol for virucidal activity employed in this example uses human rhino virus 16 (hereafter "HRV-16") as the target virus, and the MRC-5 cell line related to human tissues described by Jacobs, et al, Characteristics of Hitman 15 diploid MRC-5, Nature (London), 227, pl68-170 (1970) as the host cell for the HRV-16 viruses. Residual virus infectivity following incubation of the test substances with the virus was titrated on the MRC-5 cell line for rhinovirus growth by visually scoring the cytopathic effect (CPE) induced by virus replication through microscopic observation. More specifically, CPE was scored by observing ballooning/rounded 20 cells in the MRC-5 culture. To determine the virucidal activity, the anti-microbial composition of Example 1 (hereafter "Substance 1"), was employed at an initial dilution of 1/20 and then further diluted by serial dilutions in saline. The diluted compositions were incubated with HRV-16 for a set time period and then the reaction was terminated by adjustment 25 to a neutral pH with cell infection media. The resultant solution was then titrated out on MRC-5 cells at a dilution of 1/10 across a testing plate to carry out the infection of the cells. Each plate housed a virus control, which contained only HRV-16 infected MRC-5 cells, and a cell control, which contained only uninfected MRC-cells. The plates were further incubated for 4 days after the infection. Residual viral 30 infectivity was measured using the assay discussed above. From the results shown in Tables 1-4, all of the controls on the plate worked well. From the assay, it was concluded that Substance 1, at a 1/20 dilution, was effective in producing an HRV-16 viral log reduction of 1.50 (-log 10 TCID50) at the WO 2004/012655 PCT/US2003/023125 19 1-minute incubation period. A 1/40 dilution of Substance 1 produced a log reduction of 1.00 (-log 10 TCID50) also at the 1-minute incubation period. After the 2-minute and 5-minute incubation periods, 1/2 log reductions in HRV-16 titre were achieved. Therefore, these results tend to indicate that a 1 -minute contact time between 5 Substance I and HRV-16 would produce the most effective viral titre reduction. Table 1 shows the residual virus titres and log reductions of infectious Rhinovirus 16 on MRC-5 cells at one termination time point, of Substance 1 at different dilutions. Table 1 Dilutions pH value of Substance 1 in Isotonic solution pH value of terminated solution Virus Control (TCID50) 1 Minute Incubation Residual Virus titre (TCID50) Log Reductions (TCID50) 1/20 5.03 7.73 3.80 2.30 1.50 1/40 5.13 7.77 3.80 3.30 0.50 1/80 4.98 7.83 3.80 3.80 0.00 1/160 4.98 7.73 3.80 3.80 0.00 10 Tables 2-4 show the results of a second trial on the residual virus titres and the log reductions of infectious HRV-16 on MRC-5 cells at three different termination time points, of Substance 1 at different dilutions. 15 WO 2004/012655 PCT/US2003/023125 20 Table 2 Dilutions of Substance 1 HRV-16 Control Titre (TCID50) 1 Minute Incubation Residual HRV-16 titre (TCID50) HRV-16 log Reductions (TCID50) 1/20 3.30 1.80 1.50 1/40 3.30 2.30 1.00 1/80 3.30 2.80 0.50 1/160 3.30 2.80 0.50 1/320 3.30 2.80 0.50 Table 3 Dilutions of Substance 1 HRV-16 Control Titre (TCID50) 2 Minute Incubation Residual HRV-16 titre (TCID50) HRV-16 log Reductions (TCID50) 1/20 3.30 2.80 0.50 1/40 3.30 2.80 0.50 1/80 3.30 2.80 0.50 1/160 3.30 2.80 0.50 1/320 3.30 2.80 0.50 WO 2004/012655 PCT/US2003/023125 21 Table 4 Dilutions of Substance 1 HRV-16 Control Titre (TCID50) 5 Minute Incubation Residual HRV-16 titre (TCID50) HRV-16 log Reductions (TCID50) 1/20 3.30 2.80 0.50 1/40 3.30 2.80 0.50 1/80 3.30 3.30 0.00 1/160 3.30 2.80 0.50 1/320 3.30 2.80 0.50 Similar virucidal tests have been carried out for Substance 1 using other 5 viruses, including Herpes I Virus (HSV-1) using Vero cells as the host cell, Influenza A/Moscow/10/99, and B/Guangdong/120/00 using MDCK cells as the host cell. The results on these virucidal tests are summarized below in Tables 5-13. Tables 5-7 show the residual virus titres and log reductions of infectious HSV-10 1 on Vero cells at three different termination time points, of Substance 1 at different dilutions. Table 5 HSV-1 Control 1 Minute Incubation Substance 1 Titre (-log 10 TCID50) Residual HSV-1 titre (-log 10TCID50) HSV-1 log reductions (-log 10 TCID50) 1/40 3.80 0.00 3.80 1/80 3.80 0.00 3.80 1/160 3.80 2.80 1.00 1/320 3.80 2.80 1.00 1/640 3.80 2.80 1.00 WO 2004/012655 PCT/US2003/023125 22 T able 6 Dilutions of Substance 1 HSV-1 Control 2 Minute Incubation Titre (-log 10 TCID50) Residual HSV-1 titre (-log 10 TCID50) HSV-1 log reductions (-log 10 TCID50) 1/40 3.80 0.00 3.80 1/80 3.80 0.00 3.80 1/160 3.80 1.80 2.00 1/320 3.80 2.80 1.00 1/640 3.80 2.80 1.00 Table 7 Dilutions of Substance 1 HSV-1 Control 5 Minute Incubation Titre (-log 10 TCID50) Residual HSV-1 titre (•log 10 TCID50) HSV-1 log reductions (-log 10 TCID50) 1/40 3.80 0.00 3.80 1/80 3.80 0.00 3.80 1/160 3.80 1.80 2.00 1/320 3.80 2.80 1.00 1/640 3.80 2.80 1.00 Tables 8-10 show the residual virus titres and log reductions of influenza 10 A/Moscow/10/99 at three different termination time points, of Substance 1 at different dilutions. WO 2004/012655 PCT/US2003/023125 23 Table 8 Dilutions of Substance 1 A/Moscow Virus 1 Minute Incubation Titre (-log 10 TCID50) Residual A/Moscow titre (-log 10 TCID50) A/Moscow log reductions (-log 10 TCID50) 1/10 2.80 0.00 2.80 1/20 2.80 0.00 2.80 1/40 2.80 1.80 1.00 1/80 2.80 1.80 1.00 1/160 2.80 1.80 1.00 1/320 2.80 1.80 1.00 1/640 2.80 1.80 1.00 Citrate Buffer 2.80 1.80 1.00 Table 9 5 Dilutions of Substance 1 A/Moscow Virus 2 Minute Incubation Titre (-log 10 TCID50) Residual A/Moscow titre (-log 10 TCID50) A/Moscow log reductions (-log 10 TCID50) 1/10 2.80 0.00 2.80 1/20 2.80 0.00 2.80 1/40 2.80 1.80 1.00 1/80 2.80 1.80 1.00 1/160 2.80 1.80 1.00 1/320 2.80 1.80 1.00 1/640 2.80 1.80 1.00 Citrate Buffer 2.80 1.80 1.00 WO 2004/012655 PCT/US2003/023125 24 Table 10 Dilutions of Substance 1 A/Moscow Vims 5 Minute Incubation Titre (-log 10 TCID50) Residual A/Moscow titre (-log 10 TCID50) A/Moscow log reductions (-log 10 TCIDS0) 1/10 2.80 0.00 2.80 1/20 2.80 0.00 2.80 1/40 2.80 1.80 1.00 1/80 2.80 . 1.80 1.00 1/160 2.80 1.80 1.00 1/320 2.80 1.80 1.00 1/640 2.80 1.80 1.00 Citrate Buffer 2.80 0.00 2.80 Tables 11-13 show the residual virus titres and log reductions of Influenza B/Guangdong/120/00 at three different termination time points, of Substance 1 at different dilutions. Table 11 Dilutions of Substance 1 B/Guangdong 1 Minute Incubation Virus Titre (-log 10 TCID50) Residual B/Guangdong titre (-log 10 TCID50) B/Guangdong log reductions (-log 10 TCID50) 1/10 1.80 0.00 1.80 1/20 1.80 0.00 1.80 1/40 1.80 1.80 0.00 1/80 1.80 1.80 0.00 1/160 2.30 1.80 0.50 1/320 2.30 1.80 0.50 1/640 1.80 2.30 -0.50 Citrate Buffer 1.80 • 0.00 1.80 WO 2004/012655 PCT/US2003/023125 25 Table 12 Dilutions of Substance 1 B/Guangdong 2 Minute Incubation Virus Titre (-log 10 TCID50) Residual B/Guangdong log B/Guangdong titre reductions (-log 10 (-log 10 TCID50) TCID50) 1/10 1.80 0.00 1.80 1/20 1.80 0.00 1.80 1/40 1.80 1.80 0.00 1/80 1.80 1.80 0.00 1/160 2.30 1.80 0.50 1/320 2.30 1.80 0.50 1/640 1.80 2.80 -1.00 Citrate Buffer 1.80 0.00 1.80 Table 13 Dilutions of Substance 1 B/Guangdong 5 Minute Incubation Virus Titre (-log 10 TCID50) Residual B/Guangdong titre (-log 10 TCID50) B/Guangdong log reductions (-log 10 TCID50) 1/10 1.80 0.00 1.80 1/20 1.80 0.00 1.80 1/40 1.80 1.80 0.00 1/80 1.80 1.80 0.00 1/160 2.30 1.80 0.50 1/320 2.30 1.80 0.50 1/640 1.80 2.80 -1.00 Citrate Buffer 1.80 0.00 1.80 WO 2004/012655 PCT/US2003/023125 26 In Tables 1-13, TCID50 = -log 10TC1D50. As one can see from above results, Substance 1 is effective in inhibiting or exterminating influenza viruses and human rhinoviruses. As a result, Substance 1 5 should be effective in treating influenza and common colds. Example 4 - In Vitro Testing of Virustatic Activity of the Anti-microbial Composition The in vitro testing protocol for virucidal activity employed in this example 0 used human rhinovirus 16 (HRV-16) as the target virus, and the rhinovirus sensitive Hela cell line related to human tissues described by Conant et al, Basis for a numbering system. I. Hela cells for propagation and serologic procedure, J. Immunol., 100, pl07-l 13 (1968) as the host cell for the HRV-16 virus. The anti-microbial composition of Example 1, Substance 1, was dissolved in 5 infection media to the following dilutions: 1/20, 1/40, 1/80, 1/160 and 1/320. These dilutions were incubated on plates of MRC-5 cells for 30 minutes at 37°C (5% C02). After the incubation period, each Substance 1 dilution with MRC-5 cells in a well of the plates was subjected to HRV-16 at a known titre of 2.30 (-log 10 TCID50). Each plate housed a virus control (the Hela cells infected with HRV-16 viruses and without 0 Substance 1), a cell control (Hela cells only) and the test compound controls at the different dilutions (Hela cells with the test substance only). All the other samples on the plate contained the Hela cells infected with HRV-16 viruses and Substance 1 at different dilutions. The plates were further incubated for 4 days after infection. Residual virus infectivity following incubation of Substance 1 with the virus 5 was titrated on the Hela cell line for rhinovirus growth by measuring the cytopathic effect (CPE) induced by the virus using the following procedure. The remaining viable Hela cells after incubation with Substance 1 were stained with crystal violet solution. Excess crystal violet was removed by washing and the crystal violet stained cells were solubilized using a mixture of methanol and 0 acetic acid. The absorbance of the solution was then measured at 540 nm in an ELISA plate reader. The level of virus induced CPE was inversely proportional to the absorbance. WO 2004/012655 PCT/US2003/023125 27 The results generated from the crystal violet assay enabled the toxic concentration and the effective concentration of Substance 1 to be determined by fitting an equation, y = mx + c, wherein x corresponds to the dilution of Substance 1 and y corresponds to percentage of toxicity of Substance 1 to the cells. From this 5 equation, the TC50 (concentration at which Substance 1 indicates 50% toxicity to the cells) is at a 1/571 dilution of Substance 1. This result correlates well with the percentage of cell survivors at various dilution of Substance 1, which was also measured using the crystal violet assay, as shown in Table 14 below. 10 Table 14 Dilution of Substance 1 without Virus % Cell Survivors 1/320 89.7 1/160 94.6 1/80 97.6 1/40 109.3 1/20 168.2 Using the same equation, wherein x still corresponds to the dilution of Substance 1 and y corresponds to the percent efficacy of Substance 1 in the presence of the virus, the EC50 (concentration at which the test substance indicates 50% 15 efficacy in the presence of virus) was determined to be at a 1/91 dilution of Substance 1. This result correlates well with the percentage of viable cells at various dilutions of Substance I measured using the crystal violet assay, as shown in Table 15 below. Table 15 Substance 1 dilution and Virus % Viable Cells 1/320 + HRV-16 79.3 1/160 + HRV-16 62.3 1/80 + HRV-16 39.0 1/40 + HRV-16 15.9 1/20 + HRV-16 -220.0 20 WO 2004/012655 PCT/US2003/023125 28 In Tables 14 and 15, % Cell Survivors = (Compound only /Cell only) x 100; and % Viable Cells = (Cell only - Compound + Virus) / (Cell only — Virus only) x 100. "Compound only" denotes the measurement results for the wells containing 5 only Hela cells and Substance 1 at a predetermined dilution. "Cell only" denotes the measurement results for the wells containing only uninfected Hela cells. "Compound + Virus" denotes the measurement results for the wells containing both the Hela cells infected with HRV-16 viruses and Substance 1 at a predetermined 0 dilution. 5 0" 5 0 5 3 "Virus Only" denotes the measurement results for the wells containing the Hela cells infected with HRV-16 only. Example 5 An Anti-microbial Lozenge of the Present Invention An anti-microbial lozenge was made according to the formulation set forth below. 1) Dextrose 865.0 mg 2) Slippery Elm Bark 150.0 mg 3) Stearic Acid 75.0 mg 4) Ginger Root 105.0 mg (Children) or 140.0 mg (Adult) 5) Horseradish Root 70.0 mg 6) Honey Natural Flavor 40.0 mg 7) Turmeric Extract (5% Curcumin) 15.0 mg 8) Green Tea Leaf Extract (36% C&P) 14.0 mg 9) Silicon Dioxide 14.0 mg 10) Magnesium Stearate 12.0 mg 11) Sucralose/Splenda 4.0 mg Tablet Weight: 1364.0 mg Note: C&P as used herein means "catechols and phenols.' WO 2004/012655 PCT/US2003/023125 29 Example 6 An Anti-microbial Spray of the Present Invention An anti-microbial spray was made according to the formulation set forth below. (1) Slippery Elm Bark Extract 18.52 mg (2) Oleoresin Turmeric, Soluble (~8.5% Curcumin) 8.82 mg (3) Aquaresin Ginger 7.0 mg (4) Horseradish Flavor WONF 0.62 mg (5) Green Tea Leaf PE 50% Colorimetric 14.0 mg (6) Honey Natural Flavor 40.0 mg (7) Ethanol (95%) @ 5% 68.2 mg (8) Glycerine 603.42 mg (9) Distilled Water 603.42 mg Total Weight: 1364.0 mg Example 7 In Vitro Testing of Anti-microbial Lozenge The anti-microbial lozenge of Example 5 was tested for virucidal and virustatic activity against infection of MDCK cells with influenza viruses of the strains A/NewCaledonia/20/99 (H|N,), A/Panama/2007/99 (H3N2), and B/Guangdong/120/00. In determining virucidal the lozenge was tested at dilutions of 1/10, 1/20, 1/40, 1/80, 1/160,1/320, and 1/640. The lozenge was diluted with saline isotonic solution (Normasol). Each dilution was tested at termination points of 1, 2, and 5 minutes after the lozenge came in contact with each virus. The reaction was terminated with 1.8 ml of 0% FBS cell media. The log reductions in this example are reported as -log 10 TCID50 and were calculated using the Karber equation. WO 2004/012655 PCT/US2003/023125 30 Table 16 - The residual virus titres and log reductions of infectious A/New Caledonia/20/99 (H1N1) virus after the 1-minute termination time point at different dilutions. A/New 1 Minute Incubation r>-i Caledonia Virus _ . . . ... . Dilution f , .. Residual Virus log Tr ''S>,u Influenza titre (- reductions KJD5UJ - in rnntm 1/10 2.80 0.00 2.80 1/20 2.80 2.30 0.50 1/40 2.80 1.80 1.00 1/80 2.80 2.30 0.50 1/160 2.80 1.80 1.00 1/320 2.80 1.80 1.00 1/640 2.80 1.80 1.00 Citrate Buffer 2.80 1.80 1.00 Table 17 - The residual virus titres and log reductions of infectious A/New Caledonia/20/99 (H1N1) virus after the 2-minute termination time point at different dilutions. Dilution A/New Caledonia Virus Titre (-log 10 TCID50) 2 Minute Incubation Residual Virus log Influenza titre (- reductions log 10 TCID50) (-log 10 TCID50) I/IO 2.80 0.00 2.80 1/20 2.80 1.80 1.00 1/40 2.80 1.80 1.00 1/80 2.80 1.80 1.00 1/160 2.80 1.80 1.00 1/320 2.80 1.80 1.00 1/640 2.80 1.80 1.00 Citrate Buffer 2.80 1.80 1.00 WO 2004/012655 PCT/US2003/023125 31 Table 18 - The residual virus titres and log reductions of infectious A/New Caledonia/20/99 (H1N1) virus after the 5-minute termination time point at different dilutions. Dilution A/New Caledonia Virus Titre (-log 10 TCID50) 5 Minute Incubation Residual Virus log Influenza titre (- reductions log 10 TCID50) (-log 10 TCID50) 1/10 2.80 0.00 2.80 1/20 2.80 1.80 1.00 1/40 2.80 1.80 1.00 1/80 2.80 1.80 1.00 1/160 2.80 1.80 1.00 1/320 2.80 1.80 1.00 1/640 2.80 1.80 1.00 Citrate Buffer 2.80 1.80 1.00 Table 19 - The residual virus titres and log reductions of infectious A/Panama/2007/99 (H3N2) virus after the 1-minute termination time point at different dilutions. A/Panama Virus 1 Minu,e lncubation Dilution Titre (-log 10 Residual Virus log TCID50) Influenza titre (-. reductions 1/10 4.80 3.80 1.00 1/20 4.80 3.80 1.00 1/40 4.80 4.80 0.00 1/80 4.80 4.30 0.50 1/160 4.80 4.80 0.00 1/320 4.80 4.80 0.00 1/640 4.80 4.80 0.00 Citrate Buffer 4.80 0.00 4.80 WO 2004/012655 PCT/US2003/023125 32 Table 20 - The residual virus titres and log reductions of infectious A/Panama/2007/99 (H3N2) virus after the 2-minute termination time point at different dilutions.- A/Panama Virus 2 Minute Incubation Dilution Titre (-log 10 Residual Virus log TCID50) Influenza titre (- reductions log 10 TCID50) (-log 10 TCID50) 1/10 4.80 3.80 1.00 1/20 4.80 4.30 0.50 1/40 4.80 4.80 0.00 1/80 4.80 4.30 0.50 1/160 4.80 4.80 0.00 1/320 4.80 4.80 0.00 1/640 4.80 4.80 0.00 Citrate Buffer 4.80 2.30 2.50 5 Table 21 - The residual virus titres and log reductions of infectious A/Panama/2007/99 (H3N2) virus after the 5-minute termination time point at different dilutions. A/Panama Virus 5 Minute Incubation Dilution Titre (-log 10 Residual Virus log TCID50) Influenza titre (- reductions log 10 TCID50) (-log 10 TCID50) 1/10 4.80 3.80 1.00 1/20 4.80 4.30 0.50 1/40 4.80 4.80 0.00 1/80 4.80 4.80 0.00 1/160 4.80 4.80 0.00 1/320 4.80 4.80 0.00 1/640 4.80 4.80 0.00 Citrate Buffer ■ 4.80 2.80 2.00 WO 2004/012655 PCT/US2003/023125 33 Table 22 - The residual virus titres and log reductions of infectious B/Guangdong/120/00 virus after the 1-minute termination time . point at different dilutions. B/Guangdong 1 Minu,e lncubation Dilution Virus Titre (-log Residual Virus log 10TCID50) Influenza titre (- reductions 1/10 3.30 1.30 2.00 1/20 3.30 1.80 1.50 1/40 3.30 2.80 0.50 1/80 3.30 2.80 0.50 1/160 3.30 2.80 0.50 1/320 3.30 2.80 0.50 1/640 3.30 2.80 0.50 Citrate Buffer 3.30 0.00 3.30 Table 23 - The residual virus titres and log reductions of ifectious B/Guangdong/120/00 virus after the 2-minute termination tim point at different dilutions. Dilution B/Guangdong Virus Titre (-log 10 TCID50) 2 Minute Incubation Residual Virus log Influenza titre (- reductions log 10 TCID50) (-log 10 TCID50) l/lO 3.30 1.80 1.50 1/20 3.30 1.80 1.50 1/40 3.30 . 2.80 0.50 1/80 3.30 2.80 0.50 1/160 3.30 2.80 0.50 1/320 3.30 2.80 0.50 1/640 3.30 2.80 . 0.50 Citrate Buffer 3.30 0.00 3.30 WO 2004/012655 PCT/US2003/023125 34 Table 24 - The residual virus titres and log reductions of infectious B/Guangdong/120/00 virus after the 5-minute termination time point at different dilutions. Dilution B/Guangdong Virus Titre (-log 10 TCID50) 5 Minute Incubation Residual Virus log Influenza titre (- reductions log 10 TCID50) (-log 10 TCID50) 1/10 3.30 1.80 1.50 1/20 3.30 1.80 1.50 1/40 3.30 2.80 0.50 1/80 3.30 2.80 0.50 1/160 3.30 2.80 0.50 1/320 3.30 3.30 0.00 1/640 3.30 1.80 1.50 Citrate Buffer 3.30 0.00 3.30 5 In the viricidal assay, a known titre of Influenza virus was used as the virus control; this control underwent the same procedures as the test compound, QR-435. The Influenza titre on all plates was consistent with a virus control titre greater than 2.5 (-log 10 TCID50). 10 Example 8 In Vivo Testing of Anti-microbial Spray Five minutes before being infected with an influenza virus of the strain A/Sydney/5/97 (H3N2), four groups of six naive ferrets received intranasal doses of experimental or control compositions. The negative control group received a 15 phosphate buffer solution (PBS) placebo. The positive control group was treated with Tamiflu™ (oseltamivir phosphate, available from Roche Laboratories of Nutley, NJ). One experimental group was treated with the nasal spray of Example 6, and the other was treated with a similar nasal spray that did not include green tea extract. After the initial challenge, the ferrets were dosed with their assigned composition twice a day. 20 The ferrets in the PBS treated control group exhibited all the symptoms typical of ferrets infected with influenza A, including weight loss, fever, increased </div>

Claims

<div class="application article clearfix printTableText" id="claims"> WO 2004/012655 PCT/US2003/023125 35 inflammatory cell counts, and virus shedding on the first day after infection. The ferrets in the Tamiflu™ treated control group experienced no weight loss, no virus shedding, a reduction in inflammatory cell count rise, and no febrile illness. Both the test formulation of Example 6 and the similar nasal spray that did not 5 include green tea extract provided a low-level intermediary reduction inflammatory cell count, prevented development of a febrile illness, and delayed virus shedding that may indicate virus suppression. Ferrets treated with nasal spray according to Example 6, however, also showed some lessening of weight loss. Ferrets treated with nasal spray according to Example 6 were more active than ferrets treated with the 10 Tamiflu™. Changes may be made in carrying out the methods and to the compositions of the invention above set forth above without departing from the spirit and scope of the invention. It is intended that all matter contained in the above description shall be interpreted as illustrative and not in a limiting sense. The scope of this invention is to 15 be determined from the claims appended hereto. WHAT IS CLAIMED IS:

1. An anti-viral composition comprising: a first ingredient selected from ginger extract, ginger powder, at least a part of a whole plant of ginger, ginger tincture, and mixtures thereof; a second ingredient selected from green tea powder, green tea extract, at least a part of a whole plant of green tea, tinctures of green tea and mixtures thereof; a third ingredient selected from turmeric extract, turmeric powder, one or more curcuminoid compounds, at least a part of a whole plant of turmeric, turmeric tincture and mixtures thereof; and an acceptable carrier; wherein the first ingredient and second ingredients are present in the anti-viral composition in an amount which, when combined, is effective to reduce, treat or prevent an adverse effect of a viral infection when administered to a patient prior to expected exposure to a virus, concurrently with exposure to a virus, or after exposure to a virus.

2. The anti-viral composition of claim 1, wherein the first ingredient is selected from ginger powder extract and ginger fluid extract, and the second ingredient is selected from green tea powder, green tea powder extract and green tea fluid extract.

3. The anti-viral composition of claim 1, wherein the first ingredient comprises ginger root powder and the second ingredient comprises green tea extract.

4. The anti-viral composition of claim 3, wherein each gram of the composition contains about 5 mg to about 20 mg of green tea extract.

5. The anti-viral composition of claim 4, wherein each gram of the composition contains about 30 mg to about 150 mg of ginger root powder.

6. The anti-viral composition of claim 3. wherein each gram of the composition contains about 7 mg to about 15 mg of green tea extract. 36 intellectual property office of n.z 2 3 JAN 2007 R P r C H/r rs

7. The anti-viral composition of claim 6, wherein each gram of the composition contains about 50 mg to about 110 mg of ginger root powder.

8. The anti-viral composition of claim 1, wherein the third ingredient is one or more curcuminoid compounds.

9. The anti-viral composition of claim 1, wherein the third ingredient is selected from turmeric powder extract and turmeric fluid extract.

10. The anti-viral composition of claim 9, wherein the ingredient obtainable from turmeric comprises turmeric extract.

11. The anti-viral composition of claim 10, wherein each gram of the composition comprises from about 5 mg to about 20 mg of turmeric powder extract.

12. The anti-viral composition of claim 10, wherein each gram of the composition comprises from about 7 mg to about 15 mg of turmeric powder extract.

13. The anti-viral composition of claim 1, further comprising resveratrol.

14. An anti-viral composition comprising: turmeric extract; ginger root powder; a green tea extract; and an acceptable carrier; 1ntellectual property 37 ofrce of n.z. 2 3 JAN 2007 wherein the ginger root powder, green tea extract and turmeric extract are present in the anti-viral composition in an amount which, when combined, is effective to reduce, treat or prevent an adverse effect of viral infection when administered to a patient prior to expected exposure to a virus concurrently with exposure to a microbe, or after exposure to a virus.

15. The anti-viral composition of claim 14, further comprising resveratrol.

16. The anti-viral composition of claim 14, wherein each gram of the composition contains about 5 mg to about 20 mg of green tea extract, about 30 mg to about 150 mg of ginger root powder, and about 5 mg to about 20 mg of turmeric powder extract.

17. Use of composition comprising a first ingredient obtained from ginger; a second ingredient obtained from green tea; and an acceptable carrier: for the manufacture of a medicament for the reduction, treatment or prevention of at least one adverse effect o f a viral infection.

18. Use as claimed in claim 17 wherein the viral infection is selected from the group consisting of herpes virus, HIV virus, influenza virus, rhinovirus, and respiratory syncytial virus.

19. Use as claimed in any one of claims 17 and 18, wherein the medicament is in a form selected from a tablet, a capsule, a lozenge, a troche, a hard candy, a chewable composition, and a dental product.

20. Use as claimed in any one of claims 17-19, wherein the medicament is a nasal spray or a throat spray. intellectual property office of n.z. 2 2 MAR 200? Dc^ciwcri

21. Use as claimed in any one of claims 17-20, wherein the first ingredient is selected from ginger powder extract, ginger fluid extract, ginger powder, at least a part of a whole plant of ginger, a ginger tincture, one or more compounds contained in ginger, and mixtures thereof; and the second ingredient is selected from green tea powder, green tea powder extract, green tea fluid extract, at least a part of a whole plant of green tea, tinctures of green tea, one or more compounds contained in green tea, and mixtures thereof.

22. Use as claimed in any one of claims 17-21, wherein the first ingredient comprises ginger root powder and the second ingredient comprises green tea extract. O

3. Use as claimed in any one of claims 17-22, wherein each gram of the composition contains about 5 mg to about 20 mg of green tea extract, and about 30 mg to about 150 mg of ginger root powder.

24. Use as claimed in any one of claims 17-23, further comprising an ingredient obtained from turmcnc.

25. Use as claimed in any one of claims 1 7-24. wherein the ingredient obtained from turmeric is selected from turmeric powder extract, turmeric fluid extract', turmeric extract, one or more curcuminoid compounds, one or more other compounds contained in turmeric, turmeric powder, at least a part of a whole plant of turmeric, a turmeric tincture, and mixtures thereof.

26. Use as claimed in any one of claims 17-25, wherein the ingredient obtained from turmeric comprises turmeric extract.

27. Use as claimed in any one of claims 17-26, wherein the composition contains about 5 mg to about 20 mg of turmeric powder extract. 39 intellectual property office of n.z. 2 2 MAR 2007 received

28. Use as claimed in any one of claims 17-27, wherein the composition further comprises resveratrol.

29. An anti-viral composition of claims 1 or 14 substantially as herein described with reference to any example thereof.

30. A use of claim 17 substantially as herein described with reference to any example thereof. intellectual property office of N.Z. 1 3 SEP 2006 received </div>